Chronic Kidney disease (CKD) is one of the important complications during HIV infection. The advent of Highly Active Antiretroviral Therapy (HAART) has significantly improved the prognosis of these patients. This was a descriptive and analytical cross-sectional study of people living with HIV received at the Ambulatory Treatment Center (ATC) of the Department of Infectious Diseases of Sylvanus Olympio University Hospital (CHU-SO). The study period was 6 months from January 1, 2018 to June 30, 2018. A total of 234 patients were enrolled during the study period. The mean age of patients at initiation of treatment was 42.07 ± 9.49 years with an average duration of follow-up under antiretroviral treatment of 5.61 ± 3.22 years. The female sex was predominant (70.09%) and a sex ratio (M/F) of 0.43. Most people living with HIV were mostly classified at clinical stage 2 (30.77) and 3 (31.62%) of WHO at initiation of HAART. The mean CD4 rate was 223.30 ± 143.764 at initiation of HAART and 462.58 ± 202.723 at the time of study. The frequency of CKD was 11.11%. The majority of patients were placed in a fixed combination of Tenofovir/Lamivudine/Efavirenz in a proportion of 81.20% of cases. In univariate analysis shows that age greater than 45 years (p = 0.017). Pathological proteinuria (p = 0.021) were associated with CKD. In multivariate analysis, only age (p = 0.045) and pathological proteinuria (p = 0.035) were significantly associated with CKD.
Introduction
The prevalence of Human Immunodeficiency Virus (HIV) infection is high in the African region, with more than 25.7 million people living with HIV [1] . In 2017, Africa alone accounted for 25.7 million people living with HIV (PLHIV) [1] . In 2017, in Togo, the average prevalence in the general population aged 15 to 45 increased from 2.5% to 2.1% [2] . The survival of people living with HIV depends on several factors: early diagnosis of HIV infection, early antiretroviral therapy and especially adherence to treatment [3] [4] [5] . In 2019, in Togo, the incidence of kidney disease is high (41.8%) in HIV-infected ART naive patients [6] .
Since the advent of Highly Active Antiretroviral Therapy (HAART), the prognosis of patients has been greatly improved. There has been a decrease in the frequency of opportunistic infections and mortality [7] . Opportunistic infections accounted for more than 40% in the early 2000s, and only 15% -20% in the most recent series [8] [9] .
The increase in the life expectancy of patients treated with HAART is accompanied by an increase in the incidence of age-related diseases (diabetes and high blood pressure in particular), possible co-infections with hepatitis B and C viruses and late complications of HIV infection, including arteriosclerosis and cancers other than those defining AIDS [10] [11] [12] . These different factors contribute to the increase in the prevalence of chronic kidney disease in HIV-infected patients [13] . In Togo, this is the first ever study conducted to determine the therapeutic profile of HIV-infected patients with Chronic Kidney disease (CKD).
Patients and Methods
This was a descriptive and analytical cross-sectional study of people living with HIV received at the Ambulatory Treatment Center (ATC) of the Infectious Dis- The variables studied were sociodemographic parameters (age, sex and level of education); anthropometric parameters (weight, height and Body Mass Index (BMI)); clinical and biological parameters (WHO clinical stage of HIV (Table 3) at initiation of HAART, CD4 count) and antiretroviral therapy lines. Patients' creatinine clearance was estimated by the simplified MDRD formula [14] . CKD was defined as a clearance less than 60 ml/min/1.73 m 2 for at least 3 months.
CKD was classified into 5 stages according to K-DIGO [15] . Age was divided into two categories: higher or lower than 45 years old. This age was randomly selected.
Definition of operational terms: • High Blood Pressure (HBP) was defined as a systolic blood pressure above 140 mmHg and a diastolic blood pressure as above 90 mmHg.
• Diabetes is defined as fasting blood sugar levels above 1.21 g/l.
• BMI is classified according to WHO in 4 stages [16] . 
Results

Descriptive Aspect
A total of 1300 patients were followed at the CTA during the study period, but only 234 patients met the inclusion criteria. Of the 234 patients, 26 had CKD.
The prevalence of CKD was 11.11%. The average age of patients at initiation of treatment was 42.07 ± 9.49 and at the time of the study was 47.68 ± 9.88 with an average follow-up time on HAART of 5.61 ± 3.22 years. The female sex was predominant (70.09%) and a sex ratio (M/F) of 0.43. Of these PLHIV on HAART, 87.6% did not have a first cycle patent (Table 1) . High blood pressure was found in 13.68% of enrolled patients and diabetes in 1.71% of cases. The average body mass index (BMI) was 23.80 kg/m 2 . Overweight and obesity were 
Comparative Analysis
Univariate analysis shows that age greater than 45 years is associated (RR = 4.71, .27] (p = 0.0021)). With respect to anti-retroviral drugs administered to patients, none was associated with the occurrence of CKD (Table 8 ).
In multivariate analysis, only age and pathological proteinuria were significantly associated with CKD (OR of 5.50 (p = 0.045)) and (OR 4.11 (p = 0.045)), respectively ( Table 9 ).
Discussion
To our knowledge, this is the very first study conducted in our country to determine the antiretroviral therapeutic profile of PLHIV with CKD. The limitations of our study lie in the small size of the sample because the infectious diseases department of our center is not the only care center; however, the results found make it possible to document the African literature in the sense that it is the reference center for HIV care in Togo. Attolou gave a prevalence of 31.1% with a mean age of 34.6 ± 9.4 years [20] . In contrast, Umeizudike et al. [21] found 23.5% with an average age of 35 ± 8.3 years. It was generally accepted in Sub-Saharan Africa that CKD prevalence ranged from 6 to 48.5% in HIV-infected patients [22] . Contrary to this observation, studies conducted in Europe in caucasian subjects showed a prevalence around 4%; in France for example, it was only 4.7% in a population of 7378 patients using the MDRD formula [23] . The analysis of Hsieh M.-H. et al. [24] in Taiwan after finding a prevalence of 7.9% in its population unlike other Asian studies (15.4% in Japan and 16.8% in Hong Kong), showed that age had an impact on CKD prevalence in the HIV-infected population. It should be noted that the prevalence of CKD increased after the age of 40 [22] . Consistent with this observation, the average age of 42.07 ± 9.49 years in our study, would partly explain the superiority of our prevalence to other studies such as Umeizudike et al. [21] . In addition, the genetic susceptibility of the black subject to develop CKD must be added [25] . Nevertheless, our prevalence may be considered underestimated because of the small size of our sample.
In our study, we reported that age greater than 45 years with an OR of 5.5 (p = 0.045) was associated with the occurrence of CKD. Zannou et al. [19] in Cotonou found that age ≥ 47 years with an OR = 3.79 and IC = [1.92 -7.50] (p < 0.001) was associated with CKD; in New York Wyatt et al. [26] had found an age slightly older than 50 (p < 0.0001). The age of occurrence of CKD in HIV-infected patients is early in the majority of studies involving black subjects [20] [25] [27] .
This precocity could be explained on one hand by the genetic predisposition of [23] . Flandre et al. [23] found that having a TCD4 ≥ 200 cells/microliter with a RR of 0.63 (0.48 to 0.81) and p = 0.03 was associated with the occurrence of CKD. This correlation was not found in our study and also in others [19] [28] . HBP, diabetes and dyslipidemia are traditional risk factors for CKD in the general population and in HIV-infected patients. In our study 13.36% of patients were hypertensive. There was no correlation found between hypertension and CKD in our study. In Cotonou, Zannou et al. [19] In our study, pathological proteinuria was a risk factor for CKD. Zannou et al. [19] did not reach the same conclusion in their study in Benin. Nevertheless, the association of proteinuria with CKD in HIV-infected patients is an indicator of the importance of managing these patients. Because in the absence of treatment, it progresses on average in two years in CKD and it is responsible for 50% of cases of ESRD (End-Stage Renal Disease) [29] . The fixed-combination therapy based on Tenofovir/Lamivudine/Efavirenz was the most commonly found in our series; and no antiretroviral therapy line was associated with the occurrence of CKD. CKD involves pathophysiological changes that will influence not only the renal excretion of endogenous substances, but also the excretion of drugs and in particular HAART. The management of HAART in a patient with renal failure requires close collaboration between nephrologists and infectiologists because of the diversity of situations encountered, the multiple potential drug interactions, the variability of absorption after enteral administration and the frequency of associated acute or CKD [30] . The problem often encountered in our developing 
Conclusion
CKD is common in HIV-infected patients. The frequency of chronic kidney disease remains high with an increase related to age, comorbidities and chronic toxicity some HAART molecules. The dramatic improvement in the long-term survival of patients treated with HAART encourages better collaboration between nephrologists and infectiologists.
